Form PTO-1449 (modified)	Atty. Docket No. ARCD:374US/GNS	Serial No. 09/835,082
List of Patents and Publications for Applicant's	Applicant Mark J. Ratain, Federico Innocenti and Lalitha Iyer	
INFORMATION DISCLOSURE STATEMENT		
(Use several sheets if necessary)	Filing Date: April 12, 2001	Group: 1646

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CW	C1	Bible, et al., "Cytotoxic synergy between flavopiridol (NSSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration," *Cancer Res.*, 57:3375-3380, 1997.
	C2	Bible and Kaufmann, "Flavopiridol: acytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells," *Cancer Res.*, 56:4856-4861, 1996.
	C3	Bock et. al., In: Conjugation reactions in biotransformation, Elsevier, North Holland Biomedical Press, p. 357-364, 1978.
	C4	Carlson, et al., "Flavopiridol induces G_1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells," *Cancer Res.*, 56:2973-2978, 1996.
	C5	Cascorbi et al., "Frequency of single nucleotide polymorphisms in the p-glycoprotein drug transporter MDR1 gene in white subjects," *Clinc. Pharmacol Ther.*, 69:169-174, 2001.
	C6	Chien et al., "In vitro evaluatino of flavopiridol, a novel cell cycle inhibitor, in bladder cancer," *Cancer Chemother Pharmacol*, 44:81-87, 1999.
	C7	Coffman, et al. "The glucuronidation of opiods, other xenobiotics and androgens by human ugt2b7y(268) and ugt2by7h(268)," *Drug Metab Dispos*, 26:73-77, 1998.
	C8	Czech, et al., "Antitumoral activity of flavone L 86-8275," *nt J Oncol.*, 6:31-66, 1995.
	C9	Decleves et al., "A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encloding the P-glycoprotein," *Human Mutation*, 15: 486, 2000.

25040970.1

EXAMINER: Cynthia Walker | DATE CONSIDERED: 8/22/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:374US/GNS	Serial No. 09/835,082
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain, Federico Innocenti and Lalitha Iyer	
	Filing Date: April 12, 2001	Group: 1646

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CW	C10	Di Carlo et al., "Flavonoids: old and new aspects of a class of natural therapeutic drugs," *Life Sci.*, 65:337-353, 1999.
	C11	Diasio et al., "Clinical pharmacology of 5-fluorouracil," *Clin Pharmacokinet,* 16:215-237, 1989.
	C12	Drees et al., "Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells," *Clin Cancer Res,* 3:273-9, 1997 .
	C13	Gutmann et al., "Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro," *Drug Metab Dispos.* 27:937-941, 1999.
	C14	Hoffmeyer et al., "Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations an dcorrelation of one allele with p-glycoprotein expression and activity in vivo," *PNAS,* 28:97(7), 3473-3478, 2000.
	C15	Hooijberg et al., "Potent interaction of flavopiridol with MRP1," *British J. of Cancer,* 81:269-276, 1999..
	C16	Innocenti et al., "Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea," *Clinical Cancer Research,* 6:3400-3405, 2000.
	C17	Ito et al., "Polymorphism of the abc transporter genes mdr1, mrp1 and mrp2/cmoat, in healthy japanese subjects," *Pharmacogenetics,* 11:175-184, 2001.
	C18	Iyer, et al. "Pharmacogenetics and cancer chemotherapy," *Eur J Cancer,* 34:1493-1499, 1998.
	C19	Iyer, "Inherited variations in drug-metabolizing enzymes: significance in clinical oncology," *Mol Diagnosis,* 4:327-333, 1999.
	C20	Jager et al., "Metabolism of the anticancer drug vlavopiridol, a new inhibitor of cyclin dependent kinases in rat liver," *Life Sci.,* 62:1861-73, 1998.
	C21	Kusuhara, et al., "Reduced folate derivatives are endogenous substrates for cmoat in rats," *Am J Physiol.,* 275(4 Pt 1):G789-G796, 1998.
	C22	Lennard, "The clinical pharmacology of 6-mercaptopurine," *Eur J Clin Pharmacol.,* 43:329-339, 1992.
	C23	Levesque et al., "Isolation and characterization of UGT2B15(Y85): a udp-glucuronosyltransferase encoded by a polymorphic gene," *Pharmacogenetics* 7:317-325, 1997.

25040970.1

EXAMINER: Cynthia Walker | DATE CONSIDERED: 8/22/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:374US/GNS	Serial No. 09/835,082
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant Mark J. Ratain, Federico Innocenti and Lalitha Iyer	
(Use several sheets if necessary)	Filing Date: April 12, 2001	Group: 1646

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C24	Levesque et al., "Characterization and substrate specificity of UGT2B4 (E ^{458}: a udp-glucuronosyltransferase encoded by a polymorphic gene," *Pharmacogenetics*, 9:207-16, 1999.
	C25	Lomri et al., "Hepatocellular transport: role of atp-binding cassette proteins," *Semin. Liv. Dis.*, 16: 201-210, 1996.
	C26	Losiewicz, et al., "Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275," *Biochem Biophys Res Commun.*, 201:589-595, 1994.
	C27	Meech et al., "Determinants of udp glucuronosyltransferase membrane association and residency in the endoplasmic reticulum," *Arch Biochem Biophys.*, 356:77-85, 1998.
	C28	Miners, et al., "Drug glucuronidation in humans," *Pharmacol Ther.*, 51:347-369, 1991.
	C29	Muller et al., "ATP-dependent transport of amphiphilic cations acress the hepatocyte canalicular membrance mediated by mdr1 p-glycoprotein," *FEBS Lett.*, 343:168-172, 1994.
	C30	Nebert, "Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?" *Clin Gen*, 56:247-258, 1999.
	C31	Perdu and Germain, "Identification of novel polymorphisms in the pm5 and mrp1(abcc1) genes at locus 16p13.1 and exclusion of both genes as responsible for pseudoxanthoma elasticum," *Human Mutation*, 17:74-75, 2001.
	C32	Ramírez et al.,. "In vitro glucuronidation of flavopiridol (nsc649890) (flavo) by human liver microsomes," *Clin Pharmacol Ther.*, (abstract) 63:149, 1998.
	C33	Ratain et al., "Paradoxical relationship between acetylator phenotype and amonafide toxicity," *Clin. Pharmacol. Ther.*, 50:573-579, 1991.
	C34	Robey et al., "Overexpression of the atp-binding cassette half-transporter, abcg2 (mxr/bcrp/abcp1), in flavopiridol-resistnat human breast cancer cells," *Clinical Cancer Res.*, 7:145-152, 2001.
	C35	Rund et al, "A mutation in the promoter of the multidrug resistance gene (mdr1) in human hematological malignancies may contribute to the patogenesis of resistant disease," *Adv. Exp Med Biol.*, 457:71-75, 1999.
	C36	Sausville et al., "Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target," *Pharmacol Ther.*, 82:285-292, 1999.

25040970.1

EXAMINER: Cynthia Walker | DATE CONSIDERED: 8/22/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:374US/GNS	Serial No. 09/835,082
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Mark J. Ratain, Federico Innocenti and Lalitha Iyer	
(Use several sheets if necessary)	Filing Date: April 12, 2001	Group: 1646

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C37	Schrump et al., "Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells," *Clin Cancer Res.*, 4:2885-2890, 1998.
	C38	Senderowicz et al., "Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms," *J Clin Oncol.*, 16:2986-2999, 1998.
	C39	Shapiro et al., "Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines," *Clin. Cancer Res.*, 5:2925-2938, 1999.
	C40	Sherr, "Cancer cell cycles," *Science*, 274:1672-1677, 1996.
	C41	Stadler et al., "Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a university of chicago phase II consortium study," *J Clin Oncol.*, 18:371-375, 2000.
	C42	Thomas et al., "Phase I clinical an dpharmacokinetic trial of flavopiridol," *Proc Am Assoc Cancer Res.*, (abstract) 38:1496, 1997.
	C43	Vezmar et al., "reversal of mrp-mediated doxorubicin resistance with quinoline-based drugs," *Biochem Pharmacol.*, 59:1245-1252, 2000.
	C44	Worland et al., "Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells," *Biochem Pharmacol.*, 46:1831-1840, 1993.

25040970.1

EXAMINER: Cynthia Walker DATE CONSIDERED: 8/22/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.